Company: ZVRA
Filing Date: 2025-04-07
Form Type: DEFA14A
Source: 0001193125-25-074700
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-07
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

Zevra Therapeutics, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required |

| ☐ | Fee paid previously with preliminary materials |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

Zevra Therapeutics: Social Media Guidelines All Employee Email All, Last week, we shared an email with information about our preliminary proxy statement. Today, we want to provide clarification on our social media guidelines to ensure alignment. You are encouraged to continue to like, comment, and post about our Company on social media as usual and in accordance with our internal guidelines. Your support helps amplify the impact we are making in the rare disease community. However, it is important that you refrain from posting or interacting with any content related to the ongoing proxy contest. This includes liking, sharing, commenting on, posting, or re-postingabout any materials related to the proxy contest, proxy statement, annual meeting, nominees for election, or stockholder vote. Maintaining this distinction is essential to ensure compliance with Company policies and regulatory requirements. We encourage you to review our standard guidance below and, if you have any questions, please contact your direct supervisor or Nichol, LaDuane, Rahsaan, or Neil. When engaging with the corporate account or creating individual content, please take note of the following.

| • |     | Do: |

| • |     | Feel free to react and reshare